Table 1.

Patient characteristics, adverse events, and response to nivolumab treatment

	Patient 1	Patient 2	Patient 3
Age	47	25	55
Sex	Male	Male	Male
Prior therapies (no.)	6	6	5
Stem cell source	Matched-related	Matched-related	Haploidentical and umbilical cord blood
Conditioning regimen	Reduced intensity	Reduced intensity	Reduced intensity
T cell depleted graft	Yes	Yes	Yes
Prior GVHD	No	Chronic GVHD of gut	Chronic oral GVHD
Days to relapse following AlloHSCT (no.)	181	2456	389
Localization and size of relapse	Diffuse bone and splenic involvement	Multifocal adenopathy in mediastinum, retroperitoneum and pelvis. Largest lymph node 2.3 × 1.5 cm in mediastinum	Multifocal adenopathy in neck, chest, abdomen and pelvis. Largest lymph node 4.2 × 1.8 cm in right axilla
Prior DLI	No	Yes	No
Immune-related adverse events	Grade 2 Keratoconjunctivitis	Grade 3 Inflammatory polyarthritis and grade 2 keratoconjunctivitis	Grade 1 Rash
Response to nivolumab	Partial response	Partial response	Partial response
Duration of response	6 Months+	10 Months+	14 Months+
Donor CD3+ chimerism before and after treatment	18 to 49%	Not available	Not available